Revolade (Eltrombopag)
eltrombopag 25 mg tablet, 28 · ORAL · PBS code 14136B
AUTHORITY_REQUIREDWhat it costs
AU$1228.12 PBS-determined price per 84 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-05-01.
- • Repeats: 5.
- • PBS program: HS.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe aplastic anaemia
First line treatment
The condition must be severe aplastic anaemia; AND
Patient must not have received treatment with immunosuppressive therapy for this condition; AND
The treatment must be administered in combination with standard immunosuppressive therapy, including anti-thymocyte antibody and ciclosporin; AND
Patient must be considered ineligible for haemopoietic stem cell transplant; AND
Patient must not receive more than 24 weeks of treatment under this restriction in a lifetime.
If the application is submitted through HPOS form upload or mail, it must include:
(i) details of the proposed prescription; and
(ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).
Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.